Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.
Its localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandion’s approach has the potential to induce and sustain a more-effective response and remission in patients with many autoimmune and inflammatory conditions.
The company aims to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Pandion was founded in early 2017 and seed funded by Polaris Partners. In January 2018, the company announced announced that it closed a $58 million Series A round, co-led by Polaris, Versant Ventures, and Roche Venture Fund, with participation from SR One and BioInnovation Capital.
- Rahul Kakkar, MD CEO
- Jo Viney, PhD Co-Founder, President, and CSO
- Vikas Goyal SVP Business Development
- Alan Crane Co-Founder and Chairman
- David Sachs, MD Co-Founder